The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from several drug classes are jostling for position as second- and third-line treatment options. The availability of multiple effective therapies from various classes, combined with variations in prescribed combinations of drugs, physician preference for specific insulin regimens, and the launch of biosimilar insulins, has created a challenging market for developers.


  • How frequently are physicians prescribing combinations of T2D drugs, and which are their preferred combinations? Which factors drive or constrain physicians’ prescribing practices? What are the anticipated changes in prescribing patterns over the next 12 months?
  • What is the current patient share of GLP-1 receptor agonists such as Novo Nordisk’s Ozempic and Rybelsus and Eli Lilly’s Trulicity? What is the current patient share of SGLT-2 inhibitors such as Pfizer / Merck’s Steglatro and AstraZeneca’s Farxiga? What is the current patient share of insulins such as Sanofi’s Lantus and Eli Lilly’s Humalog?
  • How has the launch of new products such as Novo Nordisk’s Rybelsus and Pfizer / Merck’s Steglatro affected the prescribing patterns of U.S. physicians?
  • Which insulin regimens do physicians prefer to use in T2D? What percentage of T2D patients use an insulin pump versus a basal-bolus regimen?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis: Physician Insights (US)
    • Current Treatment Physician Insights - Type 2 Diabetes - US - July 2020

Author(s): Shambhavi Shukla, MTech

Shambhavi Shukla, MTech ., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at Decision Resources Group. Before joining DRG, Shambhavi was with Evalueserve for four years, where she worked closely with top pharmaceutical companies, assisting with commercial and technical ad-hoc requests. During her tenure, she delivered competitive landscape and market insight projects for various indications, including schizophrenia, multiple sclerosis, and myopia. She holds a master’s degree in biotechnology from Amity University, India.

Related Reports

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the d...

View Details

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis (US/EU)

The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging ther...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (US)

The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic therapies, the type 2 diabetes access and r...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details